Lv4
474 积分 2024-05-15 加入
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
9小时前
待确认
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
9小时前
已完结
New biological agents in systemic lupus erythematosus
18天前
已完结
TLR7 in systemic lupus erythematosus: genetics and emerging therapies
18天前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
1个月前
已完结
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
1个月前
已完结
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)
1个月前
已完结
Engasertib in Hereditary Hemorrhagic Telangiectasia
2个月前
已完结
The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis
2个月前
已完结
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
